Sodium phenylacetate inhibits the Ras/MAPK signaling pathway to induce reduction of the c-Raf-1 protein in human and canine breast cancer cells

Breast Cancer Research and Treatment

Volumn 118, Issue 2, 2009, Pages 281-291

  Watanabe, Manabu ^a   Miyajima, Nozomi ^b   Igarashi, Maki ^a   Endo, Yoshifumi ^b   Watanabe, Natsuko ^c   Sugano, Sumio ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antitumor drug; Breast cancer; C Raf 1; Ras MAPK signaling pathway; Sodium phenylacetate

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHENYLACETATE SODIUM; PHENYLACETIC ACID DERIVATIVE; PROTEIN P90; RAF PROTEIN; RAS PROTEIN; S6 KINASE; SERINE; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; DOG; DOWNSTREAM PROCESSING; DRUG INHIBITION; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOLECULE; NONHUMAN; ONCOGENE C MYC; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; DOGS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOPRECIPITATION; PHENYLACETATES; PROTO-ONCOGENE PROTEINS C-RAF; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 70350238403     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0215-y     Document Type: Article

References (43)

1. A Luini M Aguilar G Gatti, et al. 2007 Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature Breast Cancer Res Treat 101 349 353 10.1007/s10549-006-9301-1 10.1007/s10549-006-9301-1 17009109 (Pubitemid 46169889)
2. A Jemal T Murray E Ward, et al. 2005 Cancer statistics, 2005 CA Cancer J Clin 55 10 30 10.3322/canjclin.55.1.10 15661684
3. M Ellis C Ma 2007 Femara and the future: tailoring treatment and combination therapies with Femara Breast Cancer Res Treat 105 Suppl 1 105 115 10.1007/s10549-007-9697-2 10.1007/s10549-007-9697-2 1:CAS:528:DC%2BD2sXhtlektrfI 17912640
4. F Wightman DL Lighty 1982 Identification of phenylacetic acid as a natural auxin in the shoots of higher plants Physiol Plant 55 17 24 10.1111/j.1399-3054.1982.tb00278.x 10.1111/j.1399-3054.1982.tb00278.x 1:CAS:528:DyaL38XktVelsrg%3D
5. MO James RV Smith FR Williams, et al. 1972 The conjugation of phenylacetic acid in human, sub-human primates and some non primate species Proc R Soc Lond B Biol Sci 182 25 35 10.1098/rspb.1972.0064 1:CAS:528: DyaE38XkvVCkur0%3D 4403084
6. SW Brusilow M Danney LJ Waber, et al. 1984 Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis N Engl J Med 310 1630 1634 1:STN:280:DyaL2c3hvFGqtg%3D%3D 6427608
7. O Simell I Sipila J Rajantie, et al. 1986 Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate in lysinuric protein intolerance Pediatr Res 20 1117 1121 10.1203/00006450-198611000-00011 10.1203/00006450-198611000-00011 1:STN:280:DyaL2s%2FptFeisQ%3D%3D 3099249
8. D Samid S Shack LT Sherman 1992 Phenylacetate: a novel nontoxic inducer of tumor cell differentiation Cancer Res 52 1988 1992 1:CAS:528: DyaK38XitV2msr8%3D 1372534
9. M Gorospe S Shack KZ Guyton, et al. 1996 Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate Cell Growth Differ 7 1609 1615 1:CAS:528:DyaK28XnsVOiurk%3D 8959328
10. D Thibout M Kraemer M Di Benedetto, et al. 1999 Sodium phenylacetate (NaPa) induces modifications of the proliferation, the adhesion and the cell cycle of tumoral epithelial breast cells Anticancer Res 19 2121 2126 1:CAS:528:DyaK1MXmsFClu78%3D 10470159
11. D Samid Z Ram WR Hudgins, et al. 1994 Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria Cancer Res 54 891 895 1:CAS:528:DyaK2cXitVyjurY%3D 8313377
12. D Thibout M Di Benedetto M Kraemer, et al. 1998 Sodium phenylacetate modulates the synthesis of autocrine and paracrine growth factors secreted by breast cancer cell lines Anticancer Res 18 2657 2661 1:CAS:528: DyaK1cXlsF2htrc%3D 9703924
13. D Samid A Yeh P Prasanna 1992 Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate Blood 80 1576 1581 1:CAS:528:DyaK3sXhsF2gsA%3D%3D 1381630
14. J Cinatl J Cinatl P Herneiz, et al. 1994 Induction of myogenic differentiation in a human rhabdomyosarcoma cell line by phenylacetate Cancer Lett 78 41 48 10.1016/0304-3835(94)90029-9 10.1016/0304-3835(94)90029-9 1:CAS:528:DyaK2cXktVSnsrk%3D 8180967 (Pubitemid 24129080)
15. G Stockhammer GT Manley R Johnson, et al. 1995 Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate J Neurosurg 83 672 681 10.3171/jns.1995.83.4.0672 1:CAS:528:DyaK2MXpsVSgtbs%3D 7674018
16. XN Li S Parikh Q Shu, et al. 2004 Phenylbutyrate and phenylacetate induce differentiation and inhibit proliferation of human medulloblastoma cells Clin Cancer Res 10 1150 1159 10.1158/1078-0432.CCR-0747-3 10.1158/1078-0432.CCR-0747- 3 1:CAS:528:DC%2BD2cXhtFCnsr0%3D 14871995 (Pubitemid 38198917)
17. A Thibault MR Cooper WD Figg, et al. 1994 A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer Cancer Res 54 1690 1694 1:STN:280:DyaK2c7osFSjsA%3D%3D 8137283
18. SM Chang JG Kuhn HI Robins, et al. 1999 Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American brain tumor consortium report J Clin Oncol 17 984 990 1:CAS:528:DyaK1MXhvFGgu7c%3D 10071293
19. P Thompson F Balis BM Serabe, et al. 2003 Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer Cancer Chemother Pharmacol 52 417 423 10.1007/s00280-003-0674-0 10.1007/s00280-003-0674-0 1:CAS:528:DC%2BD3sXotFWmtL0%3D 12879279 (Pubitemid 37363616)
20. M Watanabe S Sugano J Imai, et al. 2001 Suppression of tumourigenicity, and induction of differentiation of the canine mammary tumour cell line MCM-B2 by sodium phenylacetate Res Vet Sci 70 27 32 10.1053/rvsc.2000.0437 10.1053/rvsc.2000.0437 1:CAS:528:DC%2BD3MXit1eqsrk%3D 11170848 (Pubitemid 33613888)
21. M Vasse D Thibout J Paysant, et al. 2001 Decrease of breast cancer cell invasiveness by sodium phenylacetate (NaPa) is associated with an increased expression of adhesive molecules Br J Cancer 84 802 807 10.1054/bjoc.2000.1648 10.1054/bjoc.2000.1648 1:CAS:528:DC%2BD3MXivVGrt78%3D 11259095 (Pubitemid 32275654)
22. L Adam M Crepin C Savin, et al. 1995 Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7ras cells in vitro and in nude mice Cancer Res 55 5156 5160 1:CAS:528:DyaK2MXpsVartbs%3D 7585564
23. S Shack LC Chen AC Miller, et al. 1995 Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion Int J Cancer 63 124 129 10.1002/ijc.2910630122 10.1002/ijc.2910630122 1:CAS:528:DyaK2MXptlyqt7c%3D 7558439
24. BP Priosoeryanto S Tateyama R Yamaguchi, et al. 1995 Establishment of a cell line (MCM-B2) from a benign mixed tumour of canine mammary gland Res Vet Sci 58 272 276 10.1016/0034-5288(95)90116-7 10.1016/0034-5288(95)90116-7 1:STN:280:DyaK2MzovVyrtQ%3D%3D 7659855
25. Q Zhou ZK Melkoumian A Lucktong, et al. 2000 Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1 J Biol Chem 275 25256 25263 10.1074/jbc.M003106200 (Pubitemid 30832545)
26. JP Alao EW Lam S Ali, et al. 2004 Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines Clin Cancer Res 10 8094 8104 10.1158/1078-0432.CCR-04-1023 10.1158/1078-0432.CCR-04-1023 1:CAS:528:DC%2BD2cXhtVCrs7vJ 15585645 (Pubitemid 39587551)
27. SR Takauji M Watanabe R Uyama, et al. 2007 Expression and subcellular localization of E-cadherin, α-catenin, and β-catenin in 8 feline mammary tumor cell lines J Vet Med Sci 69 831 834 10.1292/jvms.69.831 10.1292/jvms.69.831 1:CAS:528:DC%2BD2sXhtV2rtLrL 17827890 (Pubitemid 47367465)
28. N Miyajima M Watanabe E Ohashi, et al. 2006 Relationship between retinoic acid receptor alpha gene expression and growth-inhibitory effect of all-trans retinoic acid on canine tumor cells J Vet Intern Med 20 348 354 10.1892/0891-6640(2006)20[348:RBRARG]2.0.CO;2 10.1892/0891-6640(2006)20[348: RBRARG]2.0.CO;2 16594593
29. T Nakagawa M Watanabe E Ohashi, et al. 2006 Cyclopedic protein expression analysis of cultured canine mammary gland adenocarcinoma cells from six tumours Res Vet Sci 80 317 323 10.1016/j.rvsc.2005.07.011 10.1016/j.rvsc.2005.07.011 1:CAS:528:DC%2BD28Xhtlaqsb0%3D 16181651 (Pubitemid 43192714)
30. E Kerkhoff UR Rapp 1998 Cell cycle targets of Ras/Raf signalling Oncogene 17 1457 1462 10.1038/sj.onc.1202185 10.1038/sj.onc.1202185 1:CAS:528: DyaK1cXmsVyntbg%3D 9779991
31. D Abraham K Podar M Pacher, et al. 2000 Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation J Biol Chem 275 22300 22304 10.1074/jbc.M003259200 10.1074/jbc.M003259200 1:CAS:528: DC%2BD3cXlt1ehu7k%3D 10801873 (Pubitemid 30621814)
32. M Macaluso G Russo C Cinti, et al. 2002 Ras family genes: an interesting link between cell cycle and cancer J Cell Physiol 192 125 130 10.1002/jcp.10109 10.1002/jcp.10109 1:CAS:528:DC%2BD38Xlt1Kqurs%3D 12115718 (Pubitemid 34747780)
33. M Malumbres M Barbacid 2003 RAS oncogenes: the first 30 years Nat Rev Cancer 3 459 465 10.1038/nrc1097 10.1038/nrc1097 1:CAS:528:DC%2BD3sXktFOnsbs%3D 12778136 (Pubitemid 37328850)
34. AA Adjei 2002 Blocking oncogenic Ras signaling for cancer therapy J Natl Cancer Inst 93 1062 1074 10.1093/jnci/93.14.1062 10.1093/jnci/93.14.1062
35. JL Bos 1989 Ras oncogenes in human cancer: a review Cancer Res 49 4682 4689 1:CAS:528:DyaL1MXltlWksL4%3D 2547513
36. A Hollestelle F Elstrodt JH Nagel, et al. 2007 Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines Mol Cancer Res 5 195 201 10.1158/1541-7786.MCR-06-0263 10.1158/1541-7786.MCR-06-0263 1:CAS:528:DC%2BD2sXhvFWrtb8%3D 17314276 (Pubitemid 46424000)
37. H Mo CE Elson 2004 Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention Exp Biol Med 229 567 585 1:CAS:528:DC%2BD2cXlslWqsL8%3D
38. AS Dhillon A von Kriegsheim J Grindlay, et al. 2007 Phosphatase and feedback regulation of Raf-1 signaling Cell Cycle 6 3 7 1:CAS:528: DC%2BD2sXnvFygsLk%3D 17218791
39. D Samid S Shack CE Myers 1993 Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate J Clin Invest 91 2288 2295 10.1172/JCI116457 10.1172/JCI116457 1:CAS:528:DyaK3sXkt1Sju7k%3D 8486788
40. PG Roy AM Thompson 2006 Cyclin D1 and breast cancer Breast 15 718 727 10.1016/j.breast.2006.02.005 10.1016/j.breast.2006.02.005 16675218 (Pubitemid 44774238)
41. T Onishi K Yamakawa OE Franco, et al. 2000 p27Kip1 is the key mediator of phenylacetate induced cell cycle arrest in human prostate cancer cells Anticancer Res 20 3075 3081 1:CAS:528:DC%2BD3cXnvVCjsrc%3D 11062725
42. T Shibahara T Onishi OE Franco, et al. 2005 Down-regulation of Skp2 is correlated with p27-associated cell cycle arrest induced by phenylacetate in human prostate cancer cells Anticancer Res 25 1881 1888 1:CAS:528: DC%2BD2MXmtl2ht70%3D 16158921
43. M Henriksson B Luscher 1996 Proteins of the Myc network: essential regulators of cell growth and differentiation Adv Cancer Res 68 109 182 10.1016/S0065-230X(08)60353-X 10.1016/S0065-230X(08)60353-X 1:CAS:528: DyaK28Xktlegu7w%3D 8712067